all good going ahead.

From their latest update:

Business prospects as outlined in our Half Year’s Financial Report are expected to remain generally unchanged up to year ending 30 June 2012. The Profit Guidance given for the
full year is expected to remain the same, although order intakes have improved slightly.

From the previous profit update (7th of Feb, 2012):
The full year profits after tax for the year ending 30 June 2012 are now expected to drop by 50-60% instead of 55-65% as compared with the previous year results.


Which means that they are on track to record 2 to 2.5 cents per share (5 cents per share last FY) and will have an NTA of around 30 cents by the year end.

And 2013 is looking to be a much better picture.

We are pleased to advise that except for BioBot Surgical Pte Ltd which has undergone a re-structuring, resulting in the removal of the Founder as a CEO in November 2011 and as
a director on 28 February 2012, the commercialisation efforts for the other 3 start-up investments are expecting to take off in the next two months.

The Group does not expect the performance of the start-up investments as having any immediate impact on its 2012 results. It is confident that their contributions would be more evident from the financial year 2013 onwards.

:-)

Good luck holders!